New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

AIM ImmunoTech Inc.

Contributing Author

Recent Articles by AIM ImmunoTech Inc.

Sep-25	AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen (Rintatolimod) with Checkpoint Inhibitors AIM GlobeNewswire
Sep-22	AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth AIM GlobeNewswire
Sep-04	AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland AIM GlobeNewswire
Aug-21	AIM ImmunoTech Announces Release of the Next CEO Corner Segment AIM GlobeNewswire
Aug-15	AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update AIM GlobeNewswire
Aug-14	AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech AIM GlobeNewswire
Aug-06	AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) AIM GlobeNewswire
Aug-04	AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen Clinical Development Toward Pancreatic Cancer Approval AIM GlobeNewswire
Jul-31	AIM ImmunoTech Announces Closing of $8.0 Million Public Offering AIM GlobeNewswire
Jul-29	AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering AIM GlobeNewswire
Jul-28	AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer AIM GlobeNewswire
Jul-02	AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies AIM GlobeNewswire
Jun-20	AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements AIM GlobeNewswire
Jun-17	AIM ImmunoTech Resumes Trading on NYSE American AIM GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.